Thomas Gobbetti

Thomas Gobbetti has over 15 years of work experience in the field of translational biology. From 2022 to present, they have been the Director of Translational Biology at Engitix Therapeutics, where they are responsible for combining unique understanding of the ECM with world-class technology to generate new and more relevant therapeutics against fibrosis and solid tumors. From 2017 to 2022, they were a Scientific Leader and Translational Scientist/Veterinarian at GSK, where they provided scientific support to program and project teams for the utilization of animal models in drug discovery and development. From 2012 to 2017, they were a Postdoctoral Researcher at Queen Mary University of London, where they investigated the modulatory properties of FPR2/ALX in sepsis, myocardial ischemia and skeletal muscle regeneration. From 2011 to 2012, they were a Postdoctoral Researcher at INSERM, where they investigated how polyunsaturated fatty acids (PUFAs) metabolites signature in intestinal ischemia differs from reperfusion. From 2005 to 2011, they were a Research Fellowship as Temporary Research Associate, Animal Care Facility Operator, and Training Student at the University of Parma. During this time, they investigated the pathophysiology of serine proteinases and Protease-activated Receptors in intestinal ischemia-reperfusion injury, oversaw animal health, and researched the role of cyclooxygenases in the equine small intestine.

Thomas Gobbetti received their Bachelor of Veterinary Science from Universita degli Studi Di Parma in 2007 and their PhD in Experimental Pharmacology and Toxicology with a focus on Inflammation from the same university in 2011. Thomas also attended Queen Mary University of London, though no degree or field of study was obtained.